Elevated plasma concentration of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, in monkeys with hyperhomocyst(e)inemia.

被引：0
|
作者：
Boger, RH
Bode-Boger, SM
Heistad, DD
Lentz, SR
机构：
[1] Med Hsch Hannover, Hannover, Germany
[2] Univ Iowa, Iowa City, IA USA
来源：
CIRCULATION | 1998年 / 98卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3843
引用
收藏
页码：733 / 733
页数：1
相关论文
共 50 条
  • [1] Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia
    Böger, RH
    Bode-Böger, SM
    Sydow, K
    Heistad, DD
    Lentz, SR
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (06) : 1557 - 1564
  • [2] Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in hyperthyroid patients
    Hermenegildo, C
    Medina, P
    Peiró, M
    Segarra, G
    Vila, JM
    Ortega, J
    Lluch, S
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (12): : 5636 - 5640
  • [3] Plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell disease
    Schnog, JB
    Teerlink, T
    van der Dijs, FPL
    Duits, AJ
    Muskiet, FAJ
    ANNALS OF HEMATOLOGY, 2005, 84 (05) : 282 - 286
  • [4] Plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell disease
    J. B. Schnog
    T. Teerlink
    F. P. L. van der Dijs
    A. J. Duits
    F. A. J. Muskiet
    Annals of Hematology, 2005, 84 : 282 - 286
  • [5] Elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine in citrullinemia
    Luecke, Thomas
    Tsikas, Dimitrios
    Kanzelmeyer, Nele
    Vaske, Bernhard
    Das, Anibh Martin
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2006, 55 (12): : 1599 - 1603
  • [6] Asymmetric dimethylarginine (ADMA): An endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule
    Colonna, Vito De Gennaro
    Bianchi, Mauro
    Pascale, Valerio
    Ferrario, Paolo
    Morelli, Franca
    Pascale, Walter
    Tomasoni, Livio
    Turiel, Maurizio
    MEDICAL SCIENCE MONITOR, 2009, 15 (04): : RA91 - RA101
  • [7] Cardiovascular effects of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) and evidence for ADMA metabolism in humans in vivo
    Achan, V
    Broadhead, M
    Malaki, M
    Leiper, J
    MacAllister, R
    Vallance, P
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (06) : 303A - 303A
  • [8] Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, acts as a novel cardiovascular risk factor
    Böger, R. H.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 22 - 23
  • [9] Modulatory role of the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine (ADMA), in morphine tolerance and dependence in mice
    Gunduz, Ozgur
    Karadag, Cetin Hakan
    Ulugol, Ahmet
    JOURNAL OF NEURAL TRANSMISSION, 2010, 117 (09) : 1027 - 1032
  • [10] Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, increases the risk of cardiovascular disease and mortality in humans
    Boger, RH
    NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 2006, 14 (04): : A11 - A11
12345